Fact check: worldwide, nearly 44 million people have Alzheimer’s or a related dementia. Alzheimer’s disease accounts for 60 to 80 percent of all dementia cases. Dementia is the top cause for disabilities in later life.
A study was recently conducted by Salk Institute, with preliminary evidence that tetrahydrocannabinol (THC) and other compounds found in cannabis can promote the removal of amyloid beta on a cellular level. Amyloid beta is the toxic protein associated with the development of Alzheimer’s disease.
This research may be the first of its kind to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells. The research indicated that high levels of amyloid beta were associated with cellular inflammation and higher rates of neuron death. Exposing the cells to THC not only reduced amyloid beta protein levels, but it also eliminated the inflammatory response from the nerve cells caused by the protein, thereby allowing the nerve cells to survive.
As more and more cannabis research continues to be published, it’s important that we advocate for the safest, cleanest medicines to be available to patients worldwide. Scientists and extraction professionals trust Ai vacuum ovens, rotary evaporators, glass reactors, chillers, and vacuum pumps to reliably operate and produce top quality concentrates and distillates in labs across the world. We hope to see further research into the causes and treatments for Alzheimer’s disease.
Helpful resources for Alzheimer’s:
Alzheimer’s Foundation of America